Rocket Lab: analyst cover opens into the selloff, a defense-player framing emerges, and NASA's lunar awards pass it by
From the Space digest for 2026-10-11
What happened: Rocket Lab shares sit 54% below their 52-week high as Neutron's first flight slips again, while the company's commercial backlog keeps growing. The same coverage notes NASA's $30 billion in lunar launch awards passed Rocket Lab by. Into that weakness, Barclays initiated coverage of Rocket Lab at Overweight on Oct 9, and its $85–$90 price targets are the cover surviving the sector-wide reset — a Frankfurt-listed close of €60.90 on Friday, Oct 10 (≈ $71 at prevailing rates) capped a seven-day stretch that shaved 7.3% off the shares. TD Cowen, on the same day (Oct 9), came in the other direction: its target was cut from $120 to $90 while Buy was maintained — implying roughly 32% upside from the referenced $68.44 share price (Yahoo Finance, Oct 11, ~8:20 PM ET), a cut that lands exactly at the top of the Barclays band. Wall Street has otherwise started trimming ambitions on the name; a separate comparison piece sets Rocket Lab against Firefly Aerospace ("hypergrowth masks massive cash burn" vs "premium despite better financial discipline"). A fresh bull-case piece adds a new strategic angle: Rocket Lab's growing role as a defense player, cited among the reasons the stock could double in 2027 — a lane the prior coverage (commercial launch, NASA awards, valuation) hadn't foregrounded. And the counter-narrative layer keeps building: an Oct 11 (~4:20 PM ET) Seeking Alpha long-read frames Neutron's first launch as "the biggest test in its history" while calling the company "operationally strong, with the Iridium acquisition funded and record Electron launch contracts secured" — the funding and demand legs on record even as the valuation case (a $68/share price positioned as a would-be SpaceX challenger) hinges entirely on a rocket that hasn't flown.
What's genuinely new: A development: Rocket Lab is already a live storyline through the Iridium combination thread, and the $30B figure directly touches the "space — Moon-base logistics: NASA's $30B permanent lunar base + bulk launch procurement" storyline. New data points are the Barclays initiation and its $85–$90 targets alongside TD Cowen's $120→$90 cut (Buy intact) — two Oct 9 actions bracketing the share price — the Frankfurt close and the 7.3% seven-day figure, the 52-week gap, the NASA-award exclusion, the backlog growth framing, and the new defense-player framing in the 2027 bull case — with the Oct 11 Seeking Alpha piece adding that the Iridium acquisition is funded and Electron launch contracts are at record levels.
Watch: a firm Neutron first-flight date, whether the Barclays band and the trimmed TD Cowen $90 target hold as the Street converges, whether the defense-business lane gets concrete contracts behind the framing, and whether any of NASA's bulk-launch procurement lane opens to Rocket Lab before the gap widens.
Links: Ad hoc news — Rocket Lab's $85–$90 price targets survive a sector-wide reset · MSN/Fintel — Barclays initiates Rocket Lab at Overweight, Oct 9 · Yahoo Finance — TD Cowen cut its Rocket Lab target, still sees 32% upside · Ad hoc news — Rocket Lab's commercial backlog grows as Neutron timeline and NASA decision loom · Ad hoc news — Rocket Lab's Neutron slips and Wall Street trims its ambitions · Seeking Alpha — Rocket Lab: the biggest test in its history is coming · Ainvest — Rocket Lab is priced for a rocket that hasn't flown yet · Motley Fool — 3 reasons Rocket Lab stock could double in 2027 (defense-player angle)